

*BSW*



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gunning et al.	)	Attorney Docket:
Serial No.:	10/531,086	)	8617/94090
Filed:	June 21, 2005	)	Art Group:
For:	STEREOSPECIFIC REDUCTION OF SAPogen-3-ONES	)	1624
Examiner:	Not Yet Assigned	)	Confirmation No.:
		)	9264

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD  
 Commissioner For Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.97, a list of documents that may be material to the examination of this application is provided on the attached Form PTO/SB/08. Documents 1 to 34, listed on the attached Form 1449 are U.S. and foreign patent and pertinent articles that may be relevant to the examination of the present application. Copies of Documents 1 to 36 are bound and enclosed herewith.

Documents for which the supplied date of publication lists the year of publication without the month were published sufficiently earlier than the effective U.S. filing date and any foreign priority date, so that the particular month of publication is not in issue. Pursuant to §609 of the MPEP, it is understood

that the month of publication is not required when the particular month of publication is not in issue.

No inferences should be drawn that the attached list represents a comprehensive investigation, or that any material disclosed is equivalent to the subject invention. In addition, none of the documents that have publication dates prior to the priority date of the above application anticipate the invention in this application.

The cited documents disclose numerous specific features. There has been no attempt to list each and every feature disclosed by each document. The Examiner is requested to review the documents and determine the extent of the materiality of the document disclosures with respect to the present invention.

The discussion of any art and the citation of any document herein is not to be construed as an admission that the art or document disclosure is necessarily within the invention field of endeavor, that the art or document disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that the art or document disclosure is otherwise necessarily prior art as defined by the patent law with respect to the instant invention and application.

Also, there is reserved the right to later set forth how the instant invention is distinguished over the disclosure of any

document or other art, including the disclosures of the art and documents recited herein, that may be cited by the Examiner in rejecting a claim in the instant patent application.

The recitation herein of the art and documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

Respectfully submitted,

By Gerald T. Shekleton  
Gerald T. Shekleton, Reg. No. 27,466

Enclosures:

Form PTO/SB/08  
One Bound Volumes of Art 1 to 34  
Return Postcard

Welsh & Katz, Ltd.  
22nd Floor  
120 South Riverside Plaza  
Chicago, Illinois 60606  
312/655-1500

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, together with the stated enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on March 14, 2007.

Carol T. Shultz

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i> Sheet 1 of 3		<b>Complete if Known</b>	
		Application Number	10/531,086
		Filing Date	June 21, 2005
		First Named Inventor	Gunning et al.
		Art Unit	1624
		Examiner Name	Not Yet Assigned
Attorney Docket Number <b>8617/94090</b>			

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1	3,875,195				
2	6,150,336				
3	5,703,052				
4	5,807,834				
5	5,939,398				

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
6	WO-99/48482				T6
7	WO-99/48507				
8	WO-01/49703				
9	WO-02/079221				
10	WO-01/23406				
11	WO-02/07741				
12	WO 02079221A				

<b>OTHER ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T6
13	Helv. Chim. Acta. 66(1983) 192-217				
14	Brown et al. J. Am. Chem. Soc. 94 (1972) 7159-7161				
15	Steroids 45 (1985) 39-51				
16	J. Chem. Soc. Commun. (1982) 1239-1240				
17	Tetrahedron 40 (1984) 851-854				

Examiner Signature	/Noble Jarrell/	Date Considered	12/11/2007
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i> Sheet 2 of 3		<b>Complete if Known</b>	
		Application Number	10/531,086
		Filing Date	June 21, 2005
		First Named Inventor	Gunning et al.
		Art Unit	1624
Examiner Name	Not Yet Assigned		
		Attorney Docket Number	8617/94090

	18	Tetrahedron <b>45</b> (1989) 3717-3730	
	19	Marker et al. J. Am. Chem. Soc. <b>62</b> (1940) 2525	
	20	Marker, R.E. et al. 'Sterols. LVI. Sarsasapogenin derivatives. Epi-sarsasapogenin' J. Am. Chem. Soc. <b>61</b> (1939) 943-944	
	21	J. Nat. Prod. <b>42</b> (1979) 478-482	
	22	Ondersteopoort J. Vet. Res. <b>61</b> (1994) 351-359	
	23	Lajis Nordin, H. et al. 'Epi-sarsasapogenin and epi-smilagenin: Two sapogenins isolated from the rumen content of sheep intoxicated by Brachiaria decumbens' Steroids <b>58</b> 8 (1993) 387-389	
	24	Bungaard, H. 'Advanced Drug Delivery Reviews' <b>8</b> (1992) 1-38	
	25	Kakeya, N. et al. Chem. Pharm. Bull. <b>32</b> (1984) 692	
	26	Rouessac et al. 'Une voie d'accès à la trimethyl-4, 4, 7a-tetrahydro-3a.alpha.,4,7,7a.alpha.(3H)-benzofuranone-2 a partir des alcoxy-5-trimethyl-4, 4, 7a-hydroxy-	
		3a.alpha.,4,5,6,7a.alpha.(3H)-benzofuranones-2' Bulletin de la Societe Chimique de France <b>2</b> 5-6(1981) 199-203	
	27	Morita, K. 'Studies on the Sapogenins of Dioscorea tokoto Makino. III. Synthesis of Isohodeasapogenin and Some Reactions of Tokorogenin' Bulletin of the Chemical Society of Japan <b>32</b> 8(1959) 796-799	
	28	Morita, K. 'Studies on the Sapogenins of Dioscorea tokoto Makino. III. The Structure of Tokorogenin' Bulletin of the Chemical Society of Japan <b>32</b> 8(1959) 791-795	
	29	Chang, F.C. et al. 'Acylamides as Epimerization Reagents' J. Am. Chem. Soc. <b>80</b> (1958) 2906	
	30	Drogemuler, Michael et al. 'Steroidal pyrazines, synthetic advances and biological activity' Proceedings of ECSOC-2: The second international electronic conference on synthetic organic chemistry 1998 (1999) 209-225	

Examiner Signature	/Noble Jarrell/	Date Considered	12/11/2007
--------------------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

<p>10/24/2001 W&amp;K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	10/531,086
		Filing Date	June 21, 2005
		First Named Inventor	Gunning et al.
		Art Unit	1624
		Examiner Name	Not Yet Assigned
Sheet	3	of	3
		Attorney Docket Number	8617/94090

Examiner Signature	/Noble Jarrell/	Date Considered	12/11/2007
--------------------	-----------------	-----------------	------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST .16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /N.1/